Chemoinformaics analysis of 13-Methoxydihydronitidine
| Molecular Weight | 379.412 | nRot | 3 |
| Heavy Atom Molecular Weight | 358.244 | nRig | 25 |
| Exact Molecular Weight | 379.142 | nRing | 5 |
| Solubility: LogS | -6.445 | nHRing | 2 |
| Solubility: LogP | 4.304 | No. of Aliphatic Rings | 2 |
| Acid Count | 0 | No. of Aromatic Rings | 3 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 49 | No. of Aliphatic Hetero Cycles | 2 |
| No. of Heavy Atom | 28 | No. of Aromatic Carbocycles | 3 |
| nHetero | 6 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 21 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 22 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 1 | No. of Arom Atom | 16 |
| No. of Oxygen atom | 5 | No. of Arom Bond | 17 |
| nHA | 6 | APOL | 55.8527 |
| nHD | 0 | BPOL | 31.4573 |
| QED | 0.674 |
| Synth | 3.179 |
| Natural Product Likeliness | 1.05 |
| NR-PPAR-gamma | 0.022 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.984 |
| Pgp-sub | 0.988 |
| HIA | 0.002 |
| CACO-2 | -4.797 |
| MDCK | 0.0000681 |
| BBB | 0.133 |
| PPB | 0.902246 |
| VDSS | 0.85 |
| FU | 0.018495 |
| CYP1A2-inh | 0.939 |
| CYP1A2-sub | 0.957 |
| CYP2c19-inh | 0.897 |
| CYP2c19-sub | 0.853 |
| CYP2c9-inh | 0.516 |
| CYP2c9-sub | 0.888 |
| CYP2d6-inh | 0.875 |
| CYP2d6-sub | 0.905 |
| CYP3a4-inh | 0.858 |
| CYP3a4-sub | 0.74 |
| CL | 12.188 |
| T12 | 0.134 |
| hERG | 0.04 |
| Ames | 0.565 |
| ROA | 0.063 |
| SkinSen | 0.85 |
| Carcinogencity | 0.848 |
| EI | 0.025 |
| Respiratory | 0.869 |
| NR-Aromatase | 0.824 |
| Antiviral | Yes |
| Prediction | 0.792012 |